Japanese database study tracks Real-World use of eye injection aflibercept 8 mg
NCT ID NCT06929143
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study examines how aflibercept 8 mg, an injection into the eye, is used in routine care for patients in Japan with age-related macular degeneration or diabetic macular edema. Researchers will analyze claims data from about 3000 patients to understand patient characteristics and treatment patterns over one year. No additional visits or tests are required.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aflibercept (Eylea) 8 mg injection into the eye
- What this could lead to
- If successful, this study will provide real-world data on how aflibercept 8 mg is used in Japanese patients, potentially guiding better treatment patterns for nAMD and DME.
- What could go wrong
- This is an observational study using existing data, so it cannot prove cause and effect. Results may be limited by data quality and may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Samples will be taken from the DeSC healthcare insurance database. This database contains information of 12 million individuals and has in a previous study been found to be demographically distributed in a similar manner to the Japanese population.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are prescribed aflibercept 8 mg during the observable period from the collected data. Exclusion Criteria: * Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged \<40 years old. * Patients in the DME cohort or others who are aged \<18 years old. * Female patients who have any pregnancy-related records. * Patients who do not have at least 365 days of continuous enrollment in the database.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic macular edema (DME) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bayer
Osaka, 5300001, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Dose eye injection tested against stubborn diabetic swelling
- One eye injection, four targets: GenSci148 tested against retinal swelling
- Can one shot in the eye treat diabetic macular edema?
- Could a pill replace eye injections for diabetic vision loss?
- Can a new eye injection beat the standard for wet AMD?
- Can a One-Time gene therapy tame wet AMD for years?